Gene expression signatures of ERBB2 alterations are historically well-studied in breast cancer [38], and samples with activating ERBB2 mutations have recently been shown to share sensitivities to some small-molecule inhibitors across cancer types [39]. This evidence concerns the gene ERBB2 and cancer.